Avadel Pharmaceuticals PLC Business Update Transcript
Greetings, and welcome to the Avadel Pharmaceuticals Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.
It is now my pleasure to introduce Austin Murtagh. Thank you, and you may begin.
Good afternoon, and thank you for joining us on our conference call to discuss the final FDA approval of LUMRYZ. You can access the press release announcing the approval on our website, www.avadel.com.
As a reminder, before we begin, the following presentation includes several matters that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements.
These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |